Miscellaneous
The IMpassion130 trial was a global, randomized, double-blind, Phase III study of Atezolizumab + nab-paclitaxel vs. placebo + nab-paclitaxel in treatment naïve locally advanced or metastatic triple negative breast cancer patients. Here, progression free survival was statistically significantly longer in patients treated with the combination of Atezolizumab + nab-paclitaxel compared to placebo + nab-paclitaxel. The side effect profile was favorable as no unexpected toxicities were observed in the intervention compared to the control arm. In this podcast, Prof. Schmid provides insight on the response rate as well as the preliminary survival analysis of IMpassion130. Further possible biomarkers and the impact of the results on the treatment standard in breast cancer are discussed. Read the full Abstract on the ESMO Open website: https://esmoopen.bmj.com.